Medilink Therapeutics, based in Suzhou, has entered into another partnership agreement with German biotechnology company BioNTech SE (NASDAQ: BNTC). This collaboration allows BioNTech to utilize Medilink’s TMALIN ADC technology platform for the development of specific antibody drug conjugate (ADC) products.
According to the terms of the deal, BioNTech will make an initial payment of USD 25 million and is committed to potential development, regulatory, and commercial milestone payments totaling up to USD 1.8 billion. Additionally, Medilink will receive tiered royalties based on global annual net sales. Medilink will also have priority collaboration rights when BioNTech seeks out-licensing partners for the ADC products in Greater China, which includes China mainland, Hong Kong, Macau, and Taiwan. The two companies initially partnered in October 2023 to co-develop next-generation ADCs targeting human epidermal growth factor receptor 3 (HER3) in a deal valued at USD 1 billion.- Flcube.com
